| NCT ID | NCT05259553 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Condition | Hematological Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2022-05-20 |
| Primary Completion | 2025-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2022-05-20 with a primary completion date of 2025-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis abnormalities participate in increasing VTE incidence. Yet, data on predictive biomarkers linked to VTE are limited.
Eligibility Criteria
Inclusion Criteria: * Patient affiliated to a social security regimen or beneficiary of the same * Signed written informed consent form * Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment. Exclusion Criteria: * Pregnant women * Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent * Refusing participation * Patient whose follow-up or life expectancy is less than 6 months.
Contact & Investigator
Emilie Chalayer, MD
PRINCIPAL INVESTIGATOR
CHU de Saint-Etienne
Frequently Asked Questions
Who can join the NCT05259553 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematological Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05259553 currently recruiting?
Yes, NCT05259553 is actively recruiting participants. Contact the research team at emilie.chalayer@chu-st-etienne.fr for enrollment information.
Where is the NCT05259553 trial being conducted?
This trial is being conducted at Lyon, France, Saint-Etienne, France.
Who is sponsoring the NCT05259553 clinical trial?
NCT05259553 is sponsored by Centre Hospitalier Universitaire de Saint Etienne. The principal investigator is Emilie Chalayer, MD at CHU de Saint-Etienne. The trial plans to enroll 70 participants.